A Series A label alone does not tell you how much fresh capital a company received on a particular day. This historical 2024 roundup selects examples with primary announcements and keeps second closes and follow-on A2 financings distinct. It is deliberately not a ranking, a complete list of 2024 deals, or a claim about the companies' present performance.
Four documented 2024 examples
01
Prokeep — $25 million Series A
Prokeep announced a $25 million Series A in November 2024 led by Dahlia Equity Partners. The distributor-communications software company said it intended to expand its demand-generation capabilities. Its customer and performance figures in the release are company claims, not findings independently checked by this roundup.
02
Ruckus Games — $19 million Series A
Ruckus Games' 2024 announcement describes $19 million in Series A funding for its multiplayer game development. This establishes the round reported by the studio, not a guarantee of a game launch, audience size, or return on investment. A studio's creative plan should be distinguished from a shipped title.
03
Bright Uro — $32 million total after second close
Bright Uro's October 2024 company-issued release announced the second closing of its Series A and said the round had secured $32 million in total. The $32 million is the stated total across the Series A, not necessarily the amount newly raised at the second close. Its urodynamics-device plans are not evidence of clinical outcomes.
04
Alimetry — $18 million A2 financing
Alimetry announced an oversubscribed US$18 million A2 financing in October 2024 for commercialization of its wearable gut-health monitoring device. The company called this an A2 round, so it should not be added to an earlier Series A and presented as one newly raised 2024 amount. Commercialization plans are not proof of clinical benefit.
Why round structure matters
Private funding round labels vary by company and investor. A standard Series A, a second close of an existing Series A, and an A2 financing may all appear in a search result as Series A funding, yet they are not interchangeable for a year-by-year tally. Bright Uro's wording makes the second-close distinction explicit; Alimetry's uses the A2 label.
A round announcement also may report commitments rather than the final cash available for operations, and terms such as preferences or dilution are usually not public. The face-value financing amount is useful context but not a valuation, revenue figure, clinical validation, or proof of product-market fit.
How these entries were checked
Each entry is tied to a 2024 statement issued by the company, or to a company-issued release distributed through a wire. We retained the amount and stage terminology used in those statements, and noted when the figure was a round total or an A2. The examples cover distribution software, games, medical devices, and gut-health technology without implying that these sectors outperformed other categories.
Company announcements can be accurate accounts of what was declared while still emphasizing optimistic future plans. The dates here are announcement dates, not necessarily transaction closing dates. A complete funding dataset would require a defined geography, disclosure rules, and a method for handling confidential rounds and later corrections.
Research beyond the headline
When comparing 2024 startups, record the exact wording for the stage, amount, currency, date, and whether the funding was newly committed or a final cumulative total. Read later company updates separately instead of retroactively treating 2024 plans as accomplished. For healthcare products, check regulatory and clinical evidence directly before making efficacy claims.
Funding is a risk-bearing financial event, not an endorsement of a product or an investment recommendation. This page is an editorial snapshot. Anyone making a financial decision needs current primary documents, a clear understanding of deal terms, and professional advice appropriate to their circumstances.